Celgene (CELG +1.4% to $86.92) is the subject of lots of analyst buzz after the company gave a...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG +1.4% to $86.92) is the subject of lots of analyst buzz after the company gave a positive forecast yesterday. Jefferies raises its price target to $104 from $94 while Stifel Nicolaus ups its goal to $98 from $89, with both firms maintaining Buy ratings. RBC upgrades Celgene to Outperform from Sector Perform and ups its target to $100 from $90, while Piper Jaffray upgrades the biotech to Overweight from Neutral.